COMPOSITION AND METHOD FOR TOPICAL TREATMENT OF SKIN LESIONS

• US 20110183011A1
• Filed: 04/05/2011
• Published: 07/28/2011
• Est. Priority Date: 10/03/2008
• Status: Active Grant

• Current Assignee: Winlind Skincare LLC
• Original Assignee: Winlind Skincare LLC
• Inventors: CHIOU, WIN L.
• Granted Patent: US 8,513,225 B2
• Time in Patent Office: Days
• US Class Current: 424/682
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/60 Salicylic acid; Derivatives thereof
• CPC Class Codes: A61K 31/765 Polymers containing oxygen
• CPC Class Codes: A61K 47/10 Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
• CPC Class Codes: A61K 9/0014 Skin, i.e. galenical aspects of topical compositions non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00
• CPC Class Codes: A61K 9/0043 Nose
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders
• CPC Class Codes: A61P 17/02 for treating wounds, ulcers, burns, scars, keloids, or the like
• CPC Class Codes: A61P 17/06 Antipsoriatics
• CPC Class Codes: A61P 17/10 Anti-acne agents
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 31/04 Antibacterial agents

Abstract

Disclosed herein is a composition containing a high concentration of PG is unexpectedly capable of quickly killing other bacteria, fungi, and/or virus in vitro that is indicative of its potential high efficacy in treating various skin infection. Embodiments disclosed herein relate to a composition and method for effective topical treatment of inflammatory skin lesions in mammals, comprising of a high concentration of propylene glycol alone, or in combination with an astringent. The PG at high concentrations can be regarded as an extremely effective, safe, topical, universal, microbicide.

Claims

1. A composition for treating an inflammatory skin lesion in a mammal comprising about 15% to about 99% by weight of propylene glycol and about 0.01% to about 30% by weight of at least one water-soluble aluminum astringent in a pharmaceutically acceptable dosage form to be applied topically at least once per day.

2. The composition of claim 1, wherein the topical inflammatory lesion is selected from the group consisting of acne, rosacea, psoriasis, eczema, rash, blisters, burns, herpes simplex, warts, insect bites or infestation, itch, dermatitis, shingles, atopic dermatitis, contact dermatitis, cellulitus, folliculitis, nail infections, boils, hair infections, scalp infections, impertigo, hemorrhoids, canker sore, gingivitis, periodontitis, vaginitis, nose lesion, swelling, allergy, herpes zoster, cut, surgical incision, sunburn, cracked skin, bruises, and combinations thereof.

3. The composition of claim 1, wherein said at least one water-soluble aluminum astringent is selected from among an aluminum astringent salt, an aluminum astringent complex, and combinations thereof.

4. The composition of claim 1, wherein said water-soluble aluminum astringent is aluminum sulfate, aluminum salicylate, potassium alum, aluminum acetate, aluminum ammonium sulfate, aluminum chloride, aluminum chlorohydrate, aluminum zirconium, tetrachlorohydrate, aluminum zirconium tetrachlorohydrex gly, aluminum dichlorohydrex PG complex, aluminum dichlorohydrex PEG complex, aluminum chlorohydrate glycine, aluminum zirconium pentachlorohydrate, aluminum glycinate, aluminum dichlorohydrate, aluminum sesquichlorohydrate, aluminum sesquichlorohydrex PEG, aluminum sesquichlorohydrex PG, aluminum zirconium octachlorohydrate, aluminum zirconium octachlorohydrex gly, aluminum zirconium pentachlorohydrex gly, aluminum zirconium trichlorohydrate, aluminum zirconium trichlorohydrex gly, or any combination thereof.

5. The composition of claim 1, further comprising a steroidal anti-inflammatory compound ranging from about 0.01% to about 3% by weight.

6. The composition of claim 1, further comprising a nonsteroidal anti-inflammatory compound ranging from about 0.01% to about 30% by weight.

7. The composition of claim 1, further comprising one or more agents selected from the group consisting of water, propylene-glycol mixable solvents, pH modifiers, tissue-healing agents, skin-peeling agents, absorption enhancers, soothing agents, humectants, emulsifiers, thickeners, gelling agents, analgesics, anesthetics, antimicrobials, moisturizers, fragrances, preservatives, skin conditioners, and combinations thereof.

9. The composition of claim 1, wherein the concentration of propylene glycol ranges from about 20% to about 99% by weight.

10. The composition of claim 1, wherein the concentration of propylene glycol ranges from about 30% to about 99% by weight.

11. The composition of claim 1, wherein the concentration of propylene glycol ranges from about 40% to about 99% by weight.

12. The composition of claim 1, wherein the concentration of propylene glycol ranges from about 50% to about 99% by weight.

13. The composition of claim 1, wherein the concentration of propylene glycol ranges from about 60% to about 99% by weight.

14. The composition of claim 1, wherein the concentration of propylene glycol ranges from about 70% to about 99% by weight.

15. A method for treating a topical lesion in a mammal, which comprises:

topically administering the composition of claim 1 to the mammal in need thereof.

16. A method for treating a topical lesion in mammal, which comprises:

topically administering the composition of claim 2 to the mammal in need thereof.

17. A method for treating a topical lesions in a mammal, which comprises:

topically administering the composition of claim 3 to the mammal in need thereof.

18. A method for treating a topical lesion in a mammal, which comprises:

topically administering the composition of claim 4 to the mammal in need thereof.

19. A method for treating a topical lesion in a mammal, which comprises:

topically administering the composition of claim 5 to the mammal in need thereof.

20. A method for treating a topical lesion in a mammal, which comprises:

topically administering the composition of claim 6 to the mammal in need thereof.

21. A method for treating a topical lesion in a mammal, which comprises:

topically administering the composition of claim 7 to the mammal in need thereof.

23. A method for treating a topical lesion in a mammal, which comprises:

topically administering the composition of claim 9 to the mammal in need thereof.

24. A method for treating a topical lesion in a mammal, which comprises:

topically administering the composition of claim 10 to the mammal in need thereof.

25. A method for treating a topical lesion in a mammal, which comprises:

topically administering the composition of claim 11 to the mammal in need thereof.

26. A method for treating a topical lesion in a mammal, which comprises:

topically administering the composition of claim 12 to the mammal in need thereof.

27. A method for treating a topical lesion in a mammal, which comprises:

topically administering the composition of claim 13 to the mammal in need thereof.

28. A method for treating a topical lesion in a mammal, which comprises:

topically administering the composition of claim 14 to the mammal in need thereof.

8. A topical composition for treating skin lesions comprising from about 20% to about 99% by weight of propylene glycol in a pharmaceutical acceptable dosage form to be applied to lesion sites as a thin layer at least once per day, wherein the skin lesions are selected from the group consisting of herpes simplex, warts, shingles, nail infections, canker sore, cellulitus, folliculitis, scalp infections, hair infections, boils, gingivitis, periodontitis, impertigo, itch, psoriasis, eczema, dermatitis, and atopic dermatitis.

22. A method for treating a topical lesion in a mammal, which comprises:

topically administering the composition of claim 8 to the mammal in need thereof.